Pfizer’s Centres for Therapeutic Innovation (CTI) has teamed up with seven New York research hospitals to accelerate biomedical research into life-saving medicines, with a focus on biologics.
Genzyme will build a second manufacturing plant in Geel, Belgium to ensure it has the capacity to meet demand for its Pompe disease drugs Myozyme and Lumizyme.
French contract research organisation (CRO) CIT will work on in vitro toxicity testing for pharmaceutical and cosmetic ingredients as the newest member of the European “ScreenTox” network.
Merck plans to cash in on the biogenerics industry after forming a partnership with Parexel to develop copies of biologic drugs within its Merck BioVentures division.
Enlight Biosciences, a Boston, US-based drug discovery and development technologies company, has formed the new company, Entrega, which focuses on oral drug delivery techniques.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at BioDelivery Sciences, SOCMA and Sanofi-aventis.
Drug developers are “aggressively changing” research and development (R&D) methods in the pursuit of the next blockbuster, according to the Tufts Centre for the Study of Drug Development (Tufts CSDD).
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Followed the news in 2010? Then test your knowledge of biopharm in 2010 against colleagues, peers and our community of readers in our exclusive map-based quiz.
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
ProJect Pharmaceutics has opened its Munich headquarters and laboratory facilities in Martinsreid, Germany, beginning business operations to transform proteins, peptides and small molecules into novel drugs.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
Advinus Therapeutics is to use Corning Epic label-free detection to provide clients in India and abroad with biologically relevant drug discovery data.
Lanxess has opened an ion exchange resin production facility in India to cater for growing pharmaceutical manufacturing sector demand for ultrapure water.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Quintiles and London Genetics will offer pharmacogenetics solutions to the biopharma industry after collaborating to help advance personalised medicine.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.
German pharmaceutical giant Merck's life science division, EMD Millipore, has launched its 'single-use' Mobius 3L CellReady Bioreactor, for use in the development and optimisation of cell culture processes.
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
Beta-Pro is addressing rising demands from drug discovery and research institutes in the hepatocyte market by expanding its site at the University of Virginia Research Park, US, with a new GLP facility.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.